Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 27, 482-489, March 1, 1967]
© 1967 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hilf, R.
Right arrow Articles by Michel, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hilf, R.
Right arrow Articles by Michel, I.

Influence of the Mammotropic Tumor MtTF4 on the Growth and Biochemistry of the R3230AC Mammary Carcinoma and Mammary Glands1

Russell Hilf, Carlton Bell and Inge Michel

Squibb Institute for Medical Research, New Brunswick, New Jersey 08903

The effect of the mammotropic tumor, MtTF4, on the growth and biochemistry of the transplantable autonomous R3230AC mammary adenocarcinoma was investigated. The MtTF4 tumor, which secretes prolactin, growth hormone, and adrenocorticotropic hormone (ACTH) did not significantly alter the growth rate of the mammary tumor but did increase glucose-6-phosphate dehydrogenase (G6PD) activity in the R3230AC neoplasm when both tumors were implanted simultaneously in the same host. When implantation of the R3230AC mammary carcinoma was performed after the MtTF4 tumor had become established, the subsequent growth of the mammary tumor was reduced and the enzyme activities in the mammary neoplasm were decreased. This decreased rate of growth of the mammary neoplasm was due in part to the adrenal hyperactivity resulting from the ACTH secretion of the mammotropic tumor, since both the growth inhibition and the decreased enzyme activities in the R3230AC carcinoma were partially reversed in the adrenalectomized tumor-bearing host. Estrogen treatment inhibited the rate of growth of the R3230AC neoplasm, in the presence or absence of the MtTF4 tumor, and this hormonal treatment induced increases in G6PD, malate dehydrogenase, and phosphoglucomutase activities in the mammary tumor. The dose of estradiol valerate administered to these animals completely prevented further growth of the MtTF4 tumor. The response of the mammary glands of the tumor-bearing hosts to the secretions of the MtTF4 tumor was reflected by elevations of the activities of all of the enzymes studied. These data are discussed in light of the proposed role of prolactin and mammary tumor growth.

1 This work was supported by Contract No. PH43-65-1050, Cancer Chemotherapy National Service Center, National Cancer Institute, NIH, Bethesda, Maryland.

Received 6/28/66. Accepted 10/ 7/66.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1967 by the American Association for Cancer Research.